• For Institutions

    • Corporate Services
    • Developers
  • Download
  • Help
  • About

    • Company Profile
    • License & Regulatory
    • Media coverage
longbridgelongbridge
longbridgelongbridge
Products
Pricing
Markets
Global Markets
Stock Screener
Information
Insights
News
Live
Academy
Affiliate Program
Promotions
PortAI
EN
English
简体中文
繁體中文
繁體中文(廣東話)Posts & comments will be shown in Cantonese
Search...
Quote ListQuote List
Overview
News
Financials
© 2025 Longbridge|Disclaimer

Event Tracking

Dec12
H.C. Wainwright Maintains Buy Rating for Vir Biotechnology with a Price Target of $15.00
11:42
Nov9
Vir Biotechnology Reports Positive Results for Chronic Hepatitis Delta Treatment SOLSTICE Trial
23:10
Nov6
Evercore ISI analyst maintains BUY rating for Vir Biotechnology
15:22
Vir Biotechnology released FY2025 Q3 earnings on November 5 After-Market EST, actual revenue USD 240 K (forecast USD 1.983 M), actual EPS USD -1.1742 (forecast USD -0.845)
00:00
Vir Biotechnology released FY2025 9 Months earnings on November 5 After-Market (EST), actual revenue USD 4.486 M, actual EPS USD -2.8556
00:00
Nov5
Vir Biotechnology reports Q3 revenue below IBES estimates and wider net loss
21:06

Schedules & Filings

Schedules
Filings
Nov5
Earning Release(EST)

FY2025 Q3 Earning Release (USD) Revenue 240 K, Net Income -163.14 M, EPS -1.1742

Aug6
Earning Release(EST)

FY2025 Q2 Earning Release (USD) Revenue 1.214 M, Net Income -110.96 M, EPS -0.8014

May7
Earning Release(EST)

FY2025 Q1 Earning Release (USD) Revenue 3.032 M, Net Income -120.97 M, EPS -0.8799

View More

Stock List

Top Gainers
Top Decliners
China Concepts
Symbol
Price
%Chg
Change
VMAR
0.9760
+156.77%
+0.596
AMCI
14.650
+101.51%
+7.380
RILY
5.720
+53.76%
+2.000
CPAC
10.640
+52.22%
+3.650
EDHL
0.5472
+43.40%
+0.166
ADGM
1.180
+41.95%
+0.349
EEX
4.950
+39.83%
+1.410
CHOW
1.080
+38.09%
+0.298
MSOX
9.500
+37.48%
+2.590
BDRX
6.500
+35.98%
+1.720
View More